BackgroundIn the last decade, there has been a revolution in chronic myeloid leukemia
treatment with the introduction of tyrosine kinase inhibitors with imatinib
mesylate becoming the frontline therapy. ObjectiveTo evaluate the therapeutic efficacy of imatinib mesylate in treating chronic
myeloid leukemia patients and to identify factors related to therapeutic efficacy.
MethodsThis retrospective study was based on information obtained from patients' records
in the Hematology Service of Hospital Universitário Walter Cantídio
of the Universidade Federal do Ceará (HUWC / UFC). All patients diagnosed
with chronic myeloid leukemia that took imatinib mesylate for a minimum of 12
months in the period from January 2001 to January 2011 were included. From a
population of 160 patients, 100 were eligible for analysis. ResultsThe study population consisted of 100 patients who were mostly male (51%) with
ages ranging between 21 and 40 years (42%), from the countryside (59%), in the
chronic phase (95%), with high-risk prognostic factors (40%); the prognosis of
high risk was not associated with complete hematologic response or complete
cytogenetic response, but correlated to complete molecular response or major
molecular response. Reticulin condensation was associated with complete
hematologic response and complete cytogenetic response. It was found that 53% of
patients had greater than 90% adherence to treatment. The high adherence was
correlated to attaining complete cytogenetic response in less than 12 months.
Moreover,20% of patients had good response. ConclusionSignificant changes are indispensable in the monitoring of patients with chronic
myeloid leukemia. Thus, the multidisciplinary team is important as it provides
access to the full treatment and not just to medications.